肿瘤细胞治疗研究
英文原题：Kymriah® (tisagenlecleucel) - An overview of the clinical development journey of the first approved CAR-T therapy.
细胞与基因疗法的出现极大地改变了肿瘤学及其他治疗领域的治疗格局。
细胞和基因疗法的出现显著改变了肿瘤学及其他治疗领域的治疗范式。Kymriah（tisagenlecleucel）是一种靶向 CD19 的基因修饰自体 T 细胞免疫疗法，目前已在主要市场获批，用于治疗复发/难治性（r/r）儿童和青年成人急性淋巴细胞白血病、r/r 弥漫大 B 细胞淋巴瘤及 r/r 滤泡性淋巴瘤。本文概述 tisagenlecleucel 的临床开发历程，包括疗效结局和安全性考量。
The emergence of cell and gene therapies has dramatically changed the treatment paradigm in oncology and other therapeutic areas. Kymriah (tisagenlecleucel), a CD19-directed genetically modified autologous T-cell immunotherapy, is currently approved in major markets for the treatment of relapsed/refractory (r/r) pediatric and young adult acute lymphoblastic leukemia, r/r diffuse large B-cell lymphoma, and r/r follicular lymphoma. This article presents a high-level overview of the clinical development journey of tisagenlecleucel, including its efficacy outcomes and safety considerations.
MEMBER ACCOUNT
登录成功会直接打开下一页。
